| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Paul Bates | Q55189597 |
| P2093 | author name string | Mary Jane Drake | |
| P2860 | cites work | Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review | Q22242702 |
| Cas9 as a versatile tool for engineering biology | Q24564294 | ||
| Multiplex genome engineering using CRISPR/Cas systems | Q24609428 | ||
| Efficient genome editing in zebrafish using a CRISPR-Cas system | Q24610828 | ||
| CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes | Q24625361 | ||
| Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study | Q24635177 | ||
| RNA-programmed genome editing in human cells | Q28044562 | ||
| Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV | Q28235281 | ||
| Highly efficient endogenous human gene correction using designed zinc-finger nucleases | Q28243157 | ||
| Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease | Q28284509 | ||
| Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures | Q28299915 | ||
| Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation | Q28300338 | ||
| One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering | Q29547524 | ||
| Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation | Q29615068 | ||
| Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression | Q29615784 | ||
| Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity | Q29615792 | ||
| CRISPR RNA-guided activation of endogenous human genes | Q29617072 | ||
| Genetic engineering of human pluripotent cells using TALE nucleases | Q29619830 | ||
| TALEN-mediated gene mutagenesis in rhesus and cynomolgus monkeys | Q33625156 | ||
| RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. | Q34025414 | ||
| Zinc finger endonuclease targeting PSIP1 inhibits HIV-1 integration | Q34058383 | ||
| Gene targeting by homologous recombination in mouse zygotes mediated by zinc-finger nucleases | Q34093764 | ||
| Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins | Q34376497 | ||
| Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus | Q34655645 | ||
| Robust, synergistic regulation of human gene expression using TALE activators | Q36644568 | ||
| Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells | Q37148527 | ||
| A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy | Q37604524 | ||
| Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial | Q38958099 | ||
| TALEN knockout of the PSIP1 gene in human cells: analyses of HIV-1 replication and allosteric integrase inhibitor mechanism | Q38983286 | ||
| Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. | Q39028341 | ||
| In vivo genome editing using a high-efficiency TALEN system | Q41438039 | ||
| Effective gene targeting in rabbits using RNA-guided Cas9 nucleases. | Q42359465 | ||
| Generation of gene-modified mice via Cas9/RNA-mediated gene targeting | Q43179830 | ||
| Heritable gene targeting in the mouse and rat using a CRISPR-Cas system. | Q47822814 | ||
| Ischemic Heart Disease in HIV-Infected and HIV-Uninfected Individuals: A Population-Based Cohort Study | Q57300568 | ||
| P433 | issue | 2 | |
| P921 | main subject | HIV | Q15787 |
| P304 | page(s) | 123-127 | |
| P577 | publication date | 2015-03-01 | |
| P1433 | published in | Current Opinion in HIV and AIDS | Q15724409 |
| P1476 | title | Application of gene-editing technologies to HIV-1 | |
| P478 | volume | 10 |
| Q52590505 | Genome editing for the treatment of tumorigenic viral infections and virus-related carcinomas. |
| Q36030989 | Leveraging Cancer Therapeutics for the HIV Cure Agenda: Current Status and Future Directions |
| Q38747535 | Pluripotent stem cells progressing to the clinic |
| Q38788187 | Recent advances in RNAi-based strategies for therapy and prevention of HIV-1/AIDS. |
| Q64290770 | Selective cell death of latently HIV-infected CD4 T cells mediated by autosis inducing nanopeptides |
| Q38832507 | TALEN gene editing takes aim on HIV. |
| Q39153976 | The therapeutic landscape of HIV-1 via genome editing |
Search more.